United Kingdom· GB-APID-42428311000001100
Tyruko 300mg/15ml concentrate for solution for infusion vials
A natalizumab product containing natalizumab, registered in United Kingdom by Sandoz Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Natalizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AG03 (natalizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Natalizumab · ATC L04AG03
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Natalizumab
- Manufacturer
- Sandoz Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AG03
- ATC class
- Natalizumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin07613421134365
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
323 interactions on record for natalizumab.
Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Natalizumab · interactions on record
323 records
- 301 severe
- 15 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Natalizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTyrukoAbacus Medicine A/S
- CzechiaTYRUKOSandoz GmbH, Kundl
- SpainTYRUKO 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONSandoz Gmbh
- BelgiumTyruko 300 mgSandoz
- SwitzerlandTyruko 300 mg / 15 ml, Konzentrat zur Herstellung einer InfusionslösungSandoz Pharmaceuticals AG
- IrelandTyruko 300 mg concentrate for solution for infusionPolpharma Biologics S.A.
- IcelandTyrukoSandoz GmbH*
- NetherlandsTyruko 300 mg concentraat voor oplossing voor infusieSandoz GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tyruko, Tysabri
- Liechtenstein · Tyruko, Tysabri
- Norway · Tyruko, Tysabri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1bef08e2-ace9-485c-b219-2b3ab2e71baf GET /v1/drugs/1bef08e2-ace9-485c-b219-2b3ab2e71baf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42428311000001100",
"desc": "Tyruko 300mg/15ml concentrate for solution for infusion vials (Sandoz Ltd)",
"form": "Solution for infusion",
"vpid": "36030311000001108",
"source": "dmd",
"vtm_id": "776876003",
"strength": "20 mg",
"substance": "Natalizumab",
"ingredient": "Natalizumab",
"supplier_code": "2074301000001102"
}See everything about natalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.